Phase I study finished
We have completed phase I study with JAK kinase inhibitors.
The JAK family of non-receptor tyrosine kinases regulates the transduction of signals from cytokines and their receptors by activating STAT transcription factors and modulating the expression of STAT-dependent genes. Excessive activation of the JAK/STAT pathway has been confirmed in immune-related diseases, where JAK kinases participate in the induction and maintenance of inflammation. The development of therapy based on the inhibition of JAK family kinases has applications in many areas: oncology by inhibiting excessive cell growth and proliferation (e.g. JAK2 inhibitor in myeloproliferative syndromes and leukemias), in immunology by regulating the secretion of pro-inflammatory cytokines (e.g. JAK1 inhibitor in chronic lung diseases inflammatory) and in transplantology due to its immunosuppressive effect (inhibition of JAK3 kinase).
The study was performed with healthy volunteers in two parts: A (single ascending dose) and B (multiple ascending dose), with different doses and placebo control.
News
GcLP quality certificate for laboratory procedures
Read more … GcLP quality certificate for laboratory procedures
Study for healthy people with a drug against Covid-19
Read more … Study for healthy people with a drug against Covid-19